Ontology highlight
ABSTRACT:
SUBMITTER: Cabral KP
PROVIDER: S-EPMC4321604 | biostudies-other | 2015
REPOSITORIES: biostudies-other
Cabral Katherine P KP Ansell Jack E JE
Vascular health and risk management 20150130
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in c ...[more]